Radiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse

Transitional cell carcinoma (TCC) of the renal pelvis and ureter is a relatively uncommon malignancy; it is estimated to account for 7% of all renal neoplasms and 5% of all urothelial malignancies in the United States [1]. Upper urinary tract carcinoma is often a multifocal process, meaning that patients with cancer localised to the upper urinary tract are at greater risk of developing transitional tumours elsewhere. Approximately 20-50% of patients with an upper urinary tract tumour will develop bladder cancer [2–4].

Radical nephroureterectomy is a routine initial therapy for most patients with TCC of the renal pelvis or ureter. Surgery alone provides sufficient loco-regional control for the majority of patients that present with early stage disease; however, the overall 5-year survival rate after surgery ranges from 0-34% for patients with locally advanced TCC of the renal pelvis and ureter. The rate of local failure is reported to be between 30 and 50%, and this is the major cause of mortality in TCC patients [2–5].

The role of adjuvant external beam radiotherapy (EBRT) in the treatment of patients with TCC of the renal pelvis and ureter is unknown. Some studies report that EBRT is not effective; therefore, EBRT is not recommended for use as a prophylactic postoperative therapy [6, 7]. In contrast, other studies report that EBRT may improve the treatment outcome when it is concurrently administered with chemotherapy in patients with resected, locally advanced, upper tract urothelial malignancies. The ability of EBRT to improve the treatment outcome for patients with locally advanced renal pelvis or ureter cancer has been assessed [8, 9], but the studies included a small patient population and were not detailed enough to draw any conclusions. In this study, we report on a relatively large group of patients with TCC of the renal pelvis and ureter who were treated with postoperative radiotherapy and intravesical chemotherapy. Therefore, this study provides a detailed evaluation of the efficacy of adjuvant radiotherapy in patients with TCC of the renal pelvis and ureter.

Among the 133 total subjects, 53 died during follow-up, four were lost during follow-up, and the remaining 76 were censored at the end of the follow-up period on 3/15/2009. The interval between surgery and initiation of RT was 26.4 days on average with a 95% confidence interval of ± 3.14 days. The median follow-up time was 26.6 months. The age of the patients ranged from 34 to 91 years, and the mean age was 67.8 years. A similar proportion of patients with similar clinical symptoms were included in the radiation (RT) and non-radiation (non-RT) groups (Table 1).

We scheduled the full postoperative adjuvant radiation dose as 46-50 Gy, but this dosage was subject to change based on unpredicted situations that arose during the course of EBRT and indicated the need for a reduced dose, such as adverse side effects and the emergence of distant metastases. The dosage was increased to between 54 and 60 Gy for patients who underwent R1 or R2 resection (12 patients). Three patients presented with distant metastases during radiation, and four patients developed ≥ grade 2 anorexia; the radiation dose was reduced to < 46 Gy in these seven cases.

Survival analyses and prognostic factors

The median survival period was 55.0 months (range, 2.8-118.6). The overall 1-, 3-, and 5-year survival rates were 82.2%, 58.8%, and 47.1%, respectively. Of the 133 patients, 67 were in the RT group and 66 were in the non-RT group. The overall survival rates for these two groups at 1, 3, and 5 years were 98.8% vs. 75.5%, 61.1% vs. 53.6%, and 49.6% vs. 44.7%, respectively. The median survival periods were 55.0 months vs. 52.4 months, respectively. There was no significant difference between the overall survival for the RT and non-RT groups (p = 0.198; Figure 2A).

When we subdivided the groups based on the tumour stage of the patients, we found a significant difference between the RT and non-RT groups for patients who had a T3 or T4 tumour stage. The median survival times of these two groups were 29.9 months vs. 11.4 months (p = 0.006) for the RT and non-RT groups, respectively (Figure 2B, C).

Univariate analysis indicated that an increased overall survival rate was significantly associated with age < 60 years, a T1 or T2 tumour stage, no synchronous LN metastases, nephroureterectomy, a R0 resection, and a lower histological grade (Table 2).

Variables	n	Survival status		pvalue		Correlation with histology
		3-y	5-y	Univariate	Multivariate	coefficient	p
Age						0.130	0.136
< 60 years	31	66.8	66.8	0.029	0.015
≥ 60 years	102	52.5	37.4
Sex						0.136	0.119
Female	50	59.3	48.4	0.402	0.153
Male	83	53.6	35.8
Tumor location						-0.064	0.463
Renal pelvis	42	59.3	59.3	0.912	0.346
Ureter	91	57.0	38.9
Tumor lesions						0.024	0.785
Solitary	117	55.0	42.9	0.612	0.340
Multiple nodules	16	52.9	26.4
pT stage						0.404	< 0.001
T1 or T2	81	76.1	61.6	< 0.001	0.001
T3 or T4	52	22.2	16.7
Synchronous LN						0.143	0.100
-	124	61.7	47.8	< 0.001	0.002
+	9	0	0
Resection modalities						-0.250	0.004
Local resection	22	33.7	33.7	0.024	0.178
Nephroureterectomy	111	63.4	50.0
Residual Disease						0.347	< 0.001
R0	108	65.9	52.2	< 0.001	0.077
R1 or R2	25	10.7	10.7
Histological grade
Grade I or II	79	71.1	56.0	< 0.001	0.465
Grade III or IV	54	33.2	28.4
EBRT						0.116	0.182
No	66	53.6	41.0	0.198	0.024
Yes	67	57.5	49.6

LN: Lymph Node; EBRT: External Beam Radiation Therapy

Using multivariate analysis, we identified several favourable predictors associated with an improved overall survival, which included age < 60 years, a T1 or T2 tumour stage, absence of synchronous LN metastases, and EBRT. The histological grade factor was determined to be significantly different using univariate analysis but not significantly different based on multivariate analysis. This result is due to multicollinearity, which arises because many of the evaluated risk factors correlate with histological grade. In this study, the histological grade correlated with the tumour stage, resection models, and presence of residual disease (Table 2).

Failure patterns

In this study, 38 (28.6%) patients experienced bladder tumour relapse. Table 3 shows the univariate and multivariate analysis for patients with and without bladder tumour relapse. The favourable predictors were associated renal pelvic TCC and irradiation of bladder. Bladder tumour relapse rates in the non-RT and RT groups were 34.8% (23/66) vs. 22.4% (15/67), respectively; however, this difference was not statistically significant (p = 0.112). Of the 67 patients who received EBRT, 14 patients did not undergo bladder irradiation; their radiation treatment focused only on the tumour bed due to either R1 or R2 resection or the patient's request. When we sub-divided the 133 patients based on bladder irradiation, a significant difference was observed in the rate of bladder tumour relapse between the two groups [38.7% (31/80) without irradiation vs. 13.2% with irradiation (7/53) (chi-square test, p = 0.001), respectively]. Figure 3 provides the bladder tumour relapse-free survival curves. The curves stabilised to approximately 50.0% after 32.8 months in patients who had not received bladder irradiation and to approximately 69.1% after 44.1 months in patients who had received bladder irradiation. There was a significant difference between the two groups (p = 0.002).

Variables	n	Bladder tumor relapse		X2	p values
		Absent (n = 95)	Present (n = 38)		univariate	multivariate
Age
< 60 years	31	23(74.2%)	8(25.8%)	0.697	0.573	0.562
≥ 60 years	102	72(70.6%)	30(29.4%)
Sex
Female	50	33(66.0%)	17(34.0%)	0.282	0.277	0.588
Male	83	62(74.7%)	21(25.3%)
Tumor location
Renal pelvis	42	36(85.7%)	6(14.3%)	0.013	0.048	0.015
Ureter	91	59(64.8%)	32(35.2%)
Tumor lesions
Solitary	117	83(70.9%)	34(29.1%)	0.736	0.628	0.352
Multiple nodules	16	12(75.0%)	4(25.0%)
pT classification
T1 or T2	81	59(72.8%)	22(27.2%)	0.653	0.255	0.256
T3 or T4	52	36(69.2%)	16(30.8%)
Synchronous LN
-	124	88(71.0%)	36(29.0%)	0.662	0.687	0.759
+	9	7(77.8%)	2(22.2%)
Resection models
Local resection	22	17(77.3%)	5(22.7%)	0.507	0.853	0.543
Radical resection	111	78(70.3%)	33(29.7%)
Residual Disease
R0	108	78(72.2%)	30(27.8%)	0.674	0.148	0.167
R1 or R2	25	17(68.0%)	8(32.0%)
Histological grade
Grade I or II	79	55(69.6%)	24(30.4%)	0.577	0.926	0.816
Grade III or IV	54	40(74.1%)	14(25.9%)
EBRT
Non-EBRT	66	43(65.2%)	23(34.8%)	0.112	0.060	0.514
EBRT w/o bladder	67	52(77.6%)	15(22.4%)
RT including bladder
No	80	49(61.3%)	31(38.7%)	0.001	0.002	< 0.001
Yes	53	46(86.8%)	7(13.2%)

No lymph node metastasis was found in pT1 or T2 patients, so patients with T3 or T4 are equal to those with AJCC stage III or IV in this study. We did not use AJCC Stage III or IV in this table, because we excluded patients with distant metastases from our study, who are also regarded as stage IV.

TCC: Transitional Cell arcinoma; LN: Lymph Node; EBRT: External Beam Radiation Therapy

Table 4 provides the failure patterns for the two groups. EBRT significantly reduced the rate of loco-regional relapse, including anatomic/tumour bed recurrence and lymph node metastases, in patients who underwent nephroureterectomy.

	Non-Radiation (n = 66)	Radiation (n = 67)	p values
Anatomic/tumor bed recurrence	4(6.9%)1	0(0%)2	0.044
LN metastases	15 (24.6%)3	6(9.5%)4	0.025
Bladder recurrence	23(34.8%)	15(22.4%)	0.112
Distant metastases	15(22.7%)	16(23.9%)	0.875

* There were 94 sites of relapse in 64 patients, including 36 and 28 patients, for the Non-RT and RT groups, respectively. LN: Lymph Node

1. Eight R1 or R2 patients with primary lesions were excluded.

2. Eight RI or R2 patients with primary lesions were excluded.

3. Five patients with synchronous LN metastases were excluded.

4. Four patients with synchronous LN metastases were excluded.

Although nephroureterectoumy is a curative therapy for the majority of patients who present with tumours limited to the ureteral muscularis, the rate of local-regional recurrence may be as high as 45% (57/126), as reported in a median 9-month follow-up study in patients with locally advanced disease [6]. In addition, persistent loco-regional disease may play an important role in the subsequent development of distant metastases. Therefore, it is important to address the role of adjuvant radiation therapy, in addition to surgery, for the local and regional control of the disease, as well as to improve the overall treatment outcome. TCC of the renal pelvis and ureter is an unusual disease with insufficient clinical data; therefore, the role of EBRT in treating this disease is unclear. Czito et al. [9] retrospectively reviewed the records of 31 patients with locally advanced TCC of the renal pelvis and ureter who underwent surgery followed by adjuvant EBRT with or without concurrent chemotherapy [methotrexate, cisplatin and vinblastine (MCV)]. The 5-year overall and disease-free survival rates were improved in patients with locally advanced upper tract urothelial malignancies who underwent resection surgery and adjuvant concurrent chemoradiotherapy. This regimen should be considered in patients with T3/4 and/or node positive upper tract TCC. Patients with advanced disease treated with surgery alone had a shorter disease-free survival (23.3 months) than those treated with combination chemoradiotherapy (45.2 months). In our study, we also found that radiotherapy significantly reduced the rate of tumour recurrence, irrespective of the pT stage or the presence of synchronous LN. However, EBRT seemed to confer an overall survival advantage only to patients with T3/T4 stage or synchronous LN.

In this study, univariate analysis indicated that an increased overall survival was significantly associated with age < 60 years, a T1 or T2 tumour stage, no synchronous LN metastases, nephroureterectomy, R0 resection and a lower histological grade. These prognostic factors are similar to those reported by Ozsahin et al. [6], Tan et al. [3], and Raman et al. [12]. Recently, Raman et al. reported a retrospective review of data collected from 10 global institutions, which included 1,249 patients with TCC of the renal pelvis and ureter. This study determined that advanced T stage, higher histological grade, and lymph node metastases were associated with a poorer survival outcome [12].

Both our univariate and multivariate analyses suggested that radiation was an effective and tolerable treatment for patients with T3 or T4 pelvis or ureteral TCC. However, there are three fundamental questions that must be answered in order to develop a comprehensive plan for performing radiotherapy in these patients:

1) What is the appropriate volume of tissue that we must irradiate to achieve the desired curative or palliative goal? The volume of tissue exposed to radiation in order to encompass the gross nodal metastases and the residual tumour, and whether to include adjacent areas of potential microscopic disease, have been controversial issues. In this study, the clinical target volume included the renal fossa, the course of the ureter to the bladder, and the paracaval and para-aortic lymph nodes, which were at risk of harbouring metastatic disease. For T1 or T2-stage patients, radiotherapy did not improve overall survival, but did delay bladder tumour relapse.

Bladder tumour recurrence following nephroureterectomy for TCC of the upper urinary tract was observed in 30-40% of patients [2, 3]. Most bladder tumour recurrences develop within 2 years following surgical resection. Cozad et al. reported that radiotherapy could significantly reduce local recurrence. There was a borderline significant increase in the overall survival (p = 0.07) for 77 patients who all had T stage renal pelvis and ureteral cancer [13]. Multivariate analysis determined that the ureteric tumour location was an independent predictor (p = 0.02) for bladder tumour relapse, with rates of 20% (25/123) for patients with renal pelvis cancer and 40% (19/47) for patients with ureteral cancer. Our results showed that the bladder tumour relapse rates were 14.3% (6/42) for renal pelvis cancer and 35.2% (32/91) for ureteric cancer (chi-square test, p = 0.013). Based on these observations, we suggest that the clinical target volume should only include the bladder for elective radiotherapy in the case of T1 or T2 patients, especially in patients with ureteric cancer, as this regimen will effectively delay bladder tumour relapse.

2) What is the planned treatment dose? Selection of the radiation dose is a complex issue for abdominal cancer, because it requires the radiation oncologist to weigh the use of a sufficiently high radiation dose against an unacceptably high risk of side effects. Radiation complications consistently increase as the radiation dose increases. In general, the post-operation adjuvant radiation dose should be between 45 and 50 Gy, as this was established to be a safe dosage for the small bowel and colon. Usually, the length of the field from cephalic to caudal is >30 cm; however, no grade toxicity was observed in this study. Chauffert et al. reported no gastrointestinal bleeding in 119 patients with advanced pancreatic cancer who received 60 Gy radiation with conventional fractions [14]. Therefore, a radiation dose between 45 and 50 Gy was acceptable to use in this study.

3) What are the chemotherapeutic regimens? Adjuvant chemotherapy with paclitaxel and carboplatin [15] or M-VAC [16] is feasible, may reduce the risk of distant metastases, and may prevent the recurrence of bladder tumour in patients with high-risk upper urinary tract carcinoma. There are a few controlled clinical trials using adjuvant or radical radiotherapy with or without chemotherapy in patients with renal pelvic and ureteric cancer; therefore, whether radiotherapy improves the treatment outcome is inconclusive. A study by Czito et al. reported that cisplatin-based chemotherapy concurrently delivered with radiation significantly improved the treatment outcome. Chemotherapy may further improve the treatment outcome if it is concurrently delivered with high-dose radiation. Unfortunately, we did not adopt adjuvant chemotherapy in this study, partly due to the lack of evidence supporting adjuvant chemotherapy at the time of our protocol design. However, all patients in this study received postoperative instillation of MMC or epidorubicin as a regional chemotherapy, and this regimen successfully reduced the recurrence of bladder tumours after surgery for upper urinary tract tumours [17]. Currently, there is not enough evidence to support replacement of systemic chemotherapy with intravesical chemotherapy.

Limitations of our study included the non-randomised design and the use of several different radiation techniques, which may have been affected by selection bias, and the fact that no systemic chemotherapy regimens were included. Although our sample size was relatively large, these issues should be addressed, preferably in a prospective study using a randomised design. However, due to the rarity of this malignancy, development of the optimal treatment strategy for patients with TCC of the renal pelvis and ureter may be impossible without collaborative efforts among multiple cancer treatment institutions.

The use of adjuvant EBRT was efficacious in the treatment of TCC of the renal pelvis or ureter, as it reduced the local recurrence for all patients and improved the overall survival for those patients with T3/T4 classification. Bladder tumour recurrence was the main cause of local recurrence, so the clinical target volume should include the whole bladder for all tumour stages. Radiotherapy and chemotherapy used in an adjuvant setting is a strategy that warrants optimization and evaluation in a prospective, randomised clinical trial setting to determine whether it can further improve treatment outcome.

Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy.